Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy(TM) Human Clinical Trial

Stock Information for Vivos Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vivos Inc

Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans
Vivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM
Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics
Vivos Inc. Provides IDE Submission Status Update - Conversion to Pre-Sub Filing Accepted by the FDA
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Radiogel(TM) Precision Radionuclide Therapy(TM) Receives FDA Breakthrough Device Designation
Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.